We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

By LabMedica International staff writers
Posted on 31 Jul 2014
Print article
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose metabolism.

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) worked with a mouse model of diet-induced diabetes, the rodent equivalent of human type II diabetes. Previous studies had shown that when these mice were prevented from producing FGF1 and then placed on a high-fat diet, they quickly developed diabetes.

In the current study, the investigators expanded research on the link between FGF1 and diabetes by greatly increasing FGF1 levels in the mice. This was done by injecting the animals with one or more doses of recombinant FGF1 (rFGF1).

Results published in the July 16, 2014, online edition of the journal Nature revealed that the single dose of rFGF1 caused potent, insulin-dependent lowering of glucose levels in diabetic mice that was dose-dependent but did not lead to hypoglycemia. Chronic pharmacological treatment with rFGF1 increased insulin-dependent glucose uptake in skeletal muscle and suppressed production of glucose in the liver to achieve whole-body insulin sensitization. The sustained glucose lowering and insulin sensitization attributed to rFGF1 were not accompanied by the side effects of weight gain, fat accumulation in the liver, and bone loss associated with current insulin-sensitizing therapies. In addition, the glucose-lowering activity of FGF1 could be dissociated from its mitogenic activity and was mediated predominantly via FGF receptor 1 signaling.

"There are many questions that emerge from this work and the avenues for investigating FGF1 in diabetes and metabolism are now wide open," said senior author Dr. Ronald M. Evans, director of the gene expression laboratory at the Salk Institute for Biological Studies. "We want to move this to people by developing a new generation of FGF1 variants that solely affect glucose and not cell growth. If we can find the perfect variation, I think we will have on our hands a very new, very effective tool for glucose control."

Related Links:

Salk Institute for Biological Studies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.